The FDA has accepted a supplemental New Drug Application submitted by Teva (NYSE:TEVA) and Medincell (OTC:MDCLF) for Uzedy ...

Teva Pharmaceuticals (TEVA) and Medincell (MEDCL) announced that the supplemental New Drug Application sNDA for UZEDY extended-release ...

Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...

The FDA is reviewing risperidone (Uzedy) extended-release injectable suspension for maintenance treatment of adults with ...

Parsippany, New Jersey Thursday, February 27, 2025, 13:00 Hrs [IST] ...

Israel-headquartered Teva Pharmaceutical Industries’ US subsidiary and France’s and Medincell announced that the supplemental ...

In the fourth quarter, U.S. sales of Ajovy rose 11% to $63 million, while Austedo grew 27% to $518 million, and Uzedy sales soared to $43 million from $9 million a year earlier. Sign up here.

The decline was partially offset by higher revenues from generic products globally and strong growth from branded drugs, Austedo, Ajovy and Uzedy, along with the sale of certain product rights.

AUSTEDO Revenue: $1.7 billion, up 36%. AJOVY Revenue: Over $0.5 billion, up 18%. UZEDY Revenue: $117 million. Generics Business Revenue: Close to $9.5 billion, up 11%. API Business Growth ...

The application leverages existing clinical data for Uzedy along with prior FDA findings on the safety of Udezy in patients ...

UZEDY is currently approved for use every one or two months as a subcutaneous long-acting injectable (LAI) for the treatment ...